Company profile

Hangzhou Zhongmei Huadong Pharmaceutical

Diversified pharma / peptide therapeutics

000963 · SZSE · China

Public Market Listing

000963SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Hangzhou Zhongmei Huadong Pharmaceutical are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(5 total)

5Total Assets

0Approved

3Phase 3 / Filed

2Phase 1–2 / Early

4Diseases

Showing 5 of 5 assets

		Target & Modality
HDG1901	Phase 3	GLP-1 receptorSmall molecule	Type 2 Diabetes
HDM1002	Phase 3	GLP-1 receptorSmall molecule	Obesity
HDM1005	Phase 3	GLP-1/GIP receptor (dual)Peptide	Obesity
HDM2020	Phase 1	FGFR2bAntibody–drug conjugate	Non-Small Cell Lung Cancer
Ganagliflozin	Preclinical / Unstaged	Sodium-glucose cotransporter 2 (SGLT2)Small molecule	Chronic Kidney Disease

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.